NeuroBo Pharmaceuticals, Inc. (NRBO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hyung-Heon Kim | CEO, President, Principal Executive & Director | 625.16k | -- | 1975 |
| Mr. Marshall H. Woodworth | CFO, Principal Financial Officer & Principal Accounting Officer | 154.5k | -- | 1958 |
| Dr. Mi-Kyung Kim | Chief Scientific Officer | -- | -- | -- |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations | -- | -- | -- |
NeuroBo Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Corporate Governance
Recent Events
- Apr 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 12, 2024S-3: Offering RegistrationsSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 28, 202410-K: Periodic Financial ReportsSee Full Filing